解説演題一覧 - ASCO DIRECT On Demand 2017

解説演題一覧 2017 年 6 月 7 日現在

肺がん

解説：後藤功一

乳がん

解説：佐伯俊昭

婦人科がん

解説：藤原恵一

消化器がん

解説：佐藤太郎

消化器（大腸）がん

解説 : 山﨑健太郎

脳腫瘍

解説：西川亮

【肺がん】 Abstract No.

表紙にもどる Authour

Title

Topic

8510

Bob T. Li, MD, MPH, FRACP

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial.

Clinical Science Symposium

2502

Enriqueta Felip, MD, PhD

Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC).

Oral Abstract Session

9019

A randomized, controlled, open label phase II study of erlotinib (E) with or without the MET antibody emibetuzumab (Emi) as first-line Giorgio V. Scagliotti, MD, PhD treatment for EGFRmt non-small cell lung cancer (NSCLC) patients who have disease control after an 8-week lead-in treatment with erlotinib.

9014

Tara C. Gangadhar, MD

Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

9012

Fernando Costa Santini, MD

Safety of retreatment with immunotherapy after immune-related Poster Discussion Session toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy.

9015

Molecular determinants of response and resistance to anti-PDMatthew David Hellmann, MD (L)1 blockade in patients with NSCLC profiled with targeted nextgeneration sequencing (NGS).

Poster Discussion Session

8518

Haruyasu Murakami, MD, PhD

A nationwide genomic screening project for small cell lung cancer in Japan (LC-SCRUM-Japan).


8500

Yi-Long Wu, MD

Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with Oral Abstract Session EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104).

8508

Jamie E. Chaft, MD

Neoadjuvant nivolumab in early-stage, resectable non-small cell lung Oral Abstract Session cancers.

8505

Taofeek Kunle Owonikoko, MD, PhD

Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study.

8503

Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung Matthew David Hellmann, MD cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.

8504

Shirish M. Gadgeel, MD





Phase II study of maintenance pembrolizumab (pembro) in extensive Oral Abstract Session stage small cell lung cancer (ES-SCLC) patients (pts).

Abstract No.

Authour

Title

Topic

9057

Eri Sugiyama, MD

Clinical features of squamous cell lung cancer with targetable gene alterations in a nationwide genomic screening network in Japan (LC- Poster Session SCRUM-Japan).

9000

Julie R. Brahmer

Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.


Cesare Gridelli, MD

Efficacy of the addition of cisplatin to single-agent first-line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): A joint analysis of the multicenter, randomized phase III MILES-3 and MILES-4 studies.


Jaafar Bennouna, MD

Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients Oral Abstract Session (pts) with advanced non-small cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo).

LBA9007

Tony Mok, MD

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): Oral Abstract Session A randomized, open-label phase 3 trial.

LBA9008

Alice T. Shaw, MD, PhD

Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

9002

9004


【乳がん】 Abstract No.


Title

Topic

Olivier Tredan

Routine molecular screening of advanced refractory cancer patients Plenary Session An analysis of the first 2490 patients of the ProfilER Study

George W. Sledge, MD

MONARCH 2: Abemaciclib in combination with fulvestrant in patients Oral Abstract Session with HR+/HER2- advanced breast cancer who progressed on endocrine therapy

Richard S. Finn, MD

Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18).

Luca Malorni, MD PhD

A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor Oral Abstract Session positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC) (TREnd trial).

1003

Edith A. Perez

Phase III, randomized study of first-line trastuzumab emtansine (TDM1) Â± pertuzumab (P) vs. trastuzumab + taxane (HT) treatment of HER2-positive MBC: Final overall survival (OS) and safety from MARIANNE.

1004

William John Gradishar, MD

Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with Oral Abstract Session HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE.

1005

Rachel A. Freedman, MD, MPH

TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast Oral Abstract Session cancer brain metastases (BCBM).

LBA4

Mark E. Robson, MD

OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast Plenary Session cancer (mBC) and a germline BRCA mutation (gBRCAm).

1006

Jelmar Quist

Association of a four-gene decision tree signature with response to platinum-based chemotherapy in patients with triple negative breast cancer.

1008

Sylvia Adams, MD

Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): Oral Abstract Session KEYNOTE-086 cohort A.

11501

Sangeetha Meda Reddy, M.D.

Immune and molecular determinants of response to neoadjuvant chemotherapy in inflammatory breast cancer.


Toshihiko Doi, MD, PhD

Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.


LBA100

1000

1001

1002

108




Abstract No.

Authour

Title

Topic

Gunter Von Minckwitz, MD, PhD

APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus Oral Abstract Session chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).

Marco Colleoni, MD

SOLE (Study of Letrozole Extension): A phase III randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women Oral Abstract Session who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer (BC).

504

Nadia Harbeck, MD, PhD

Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2negative, early breast cancer.


506

Laura Esserman, MD, MBA

Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.


LBA500

503

【婦人科がん】 Abstract No.


Title

Topic

5500

Philipp Harter (PI), MD PhD

LION: Lymphadenectomy in ovarian neoplasms—A prospective Oral Abstract Session randomized AGO study group led gynecologic cancer intergroup trial.

5501

Andreas Du Bois, MD, PhD

Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20.


5502

Stephanie M. de Boer, MD

Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer.


5505

Daniela Matei

A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.


5503

Hiroyuki Nomura

A randomized phase III trial of docetaxel plus cisplatin or paclitaxel plus carboplatin compared with doxorubicin plus cisplatin as adjuvant Oral Abstract Session chemotherapy for endometrial cancer at high risk of recurrence: Japanese Gynecologic Oncology Group study (JGOG2043).

5507

Effect of health-related quality of life (HRQOL) and patient-centered outcomes on the clinical benefit of prolongation of progression-free Michael Friedlander, MD, PhD survival (PFS) with olaparib maintenance following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial.

5504

Antoine Hollebecque, MD

An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Oral Abstract Session recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.

5513

Andrea Varga, MD

Pembrolizumab in patients (pts) with PD-L1–positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028.

5506

Jonathan A. Ledermann, MD, Overall survival results of ICON6: A trial of chemotherapy and FRCP cediranib in relapsed ovarian cancer.


5508

Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) Yolanda Garcia Garcia, M.D., with or without bevacizumab (Bev) in advanced epithelial ovarian Ph.D. cancer (EOC)‫( ‏‬GEICO 1205/NOVA TRIAL).


5510

Is the mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin (ddTC) than Ryusuke Murakami, MD, PhD to conventional taxane and carboplatin chemotherapy (TC) in high grade serous ovarian carcinoma? A survey of Japanese Gynecology Oncology Group study (JGOG3016A1).


5511

Melinda S. Yates, PhD

Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes.




【消化器がん】 Abstract No.


Title

Topic

4000

Lorenza Rimassa, MD

Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIVHCC phase III trial.

4001

Ann-Lii Cheng, MD, PhD

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma Oral Abstract Session (uHCC).

4006

John Neil Primrose, MD FRCS

Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.

4010

Keisuke Koeda, MD, PhD

ABSOLUTE: A phase 3 trial of nanoparticle albumin-bound paclitaxel (nab-PTX) versus solvent-based paclitaxel (sb-PTX) in patients with Poster Discussion Session pre-treated advanced gastric cancer (AGC)—Efficacy and QOL results.

4014

Yelena Yuriy Janjigian, MD

Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.


4012

Yung-Jue Bang, MD, PhD

KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer.


4003

Charles S. Fuchs, MD

KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.




【消化器（大腸）がん】 Abstract No.

Authour

表紙にもどる Title

Topic

3531

Thierry Andre, MD

Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high Poster Session microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.

3548

Scott Kopetz, MD, PhD, FACP

Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients Poster Session with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.

3540

Shota Fukuoka, MD

Regorafenib (REG) versus trifluridine/tipiracil (TAS-102) as salvageline in patients with metastatic colorectal cancer refractory to standard Poster Session chemotherapies (REGOTAS): A propensity score analysis from a JSCCR multicenter observational study.

3514

S. Rim Kim, MD

Tumor sidedness and intrinsic subtypes in patients with stage II/III colon cancer: Analysis of NSABP C-07 (NRG Oncology).


11508

Chiara Cremolini, MD

Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study.


Qian Shi, PhD

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

Plenary Session

3500

Thierry André, MD

Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the Oral Abstract Session International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

3501

Alberto F. Sobrero, MD

FOLFOX4/XELOX in stage II–III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial.

3502

Timothy Iveson, MD

Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of Oral Abstract Session oxaliplatin based adjuvant chemotherapy for colorectal cancer.

3504

Somatic DNA mutations, MSI status, Mutational Load (ML): Federico Innocenti, MD, PhD association with overall survival (OS) in patients (pts) with metastatic Oral Abstract Session colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance)

3507

Ricky A. Sharma, MA, MB, BChir, FRCP, FRCR, PhD

3505

Randomized trial of irinotecan and cetuximab with or without Scott Kopetz, MD, PhD, FACP vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).

3071

Luis A. Diaz, MD

LBA1

Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer.

Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.




Poster Session

【脳腫瘍】 Abstract No.


Title

Topic

2009

Martin J. Van Den Bent, MD

Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion.


2000

Mizuhiko Terasaki, MD, PhD

Randomized, double-blind, phase III trial of a personalized peptide vaccination for human leukocyte antigen-A24-positive glioblastoma multiforme patients refractory to temozolomide-based therapy.


2001

Solmaz Sahebjam, MD

Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: Oral Abstract Session CheckMate 143.

2003

Andrew B. Lassman, MD

Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.


2004

David Michael Hyman, MD

Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.


2010

Mark M. Souweidane, MD

A phase I study of convection enhanced delivery (CED) of 124I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma (DIPG).


2011

Thomas Graillon, MD, PhD

A phase II of everolimus and octreotide for patients with refractory and documented progressive meningioma (CEVOREM).


2013

Michael Weller

Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma.


2014

Hans-Georg Wirsching, MD

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: Efficacy and imaging Poster Discussion Session analyses of the ARTE trial.

2012

Phioanh Leia Nghiemphu, MD

Phase II trial of bevacizumab and temozolomide for upfront treatment Poster Discussion Session of elderly patients with newly diagnosed glioblastoma.

2017

Enrico Franceschi, MD

Low grade glioma patients with IDH mutation and 1p19q codeletion: To treat or not to treat?

2026

Roberta Ruda, MD

A phase II trial of temozolomide (TMZ) 1 week on/1 week off as initial treatment for high risk low grade oligodendroglial tumors: An AINO Poster Session (Italian Association for Neuro-Oncology) study.


Abstract No.

Authour

Title

Identification of novel therapeutic targets in glioblastoma with functional genomic mRNA profiling.

2018

Cyrillo Gerardo Brahm, MD

2019

Deepa Suresh Subramaniam, RNA-Seq analysis of glioma tumors reveal targetable gene fusions. MBBS, MD

Topic



解説演題一覧 - ASCO DIRECT On Demand 2017

Recommend Documents